142 related articles for article (PubMed ID: 32076459)
1. Identification of Protein Expression Changes in Hepatocellular Carcinoma through iTRAQ.
Zhang Y; Ying X; Zhao Q; Ma J; Zhang D; He C; Han S
Dis Markers; 2020; 2020():2632716. PubMed ID: 32076459
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma.
Qi Y; Xu F; Chen L; Li Y; Xu Z; Zhang Y; Wei W; Su N; Zhang T; Fan F; Wang X; Qin X; Zhang L; Liu Y; Xu P
Oncotarget; 2016 Oct; 7(42):68242-68252. PubMed ID: 27626164
[TBL] [Abstract][Full Text] [Related]
3. Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma.
Huang C; Wang Y; Liu S; Ding G; Liu W; Zhou J; Kuang M; Ji Y; Kondo T; Fan J
J Proteome Res; 2013 Apr; 12(4):1838-46. PubMed ID: 23442176
[TBL] [Abstract][Full Text] [Related]
4. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.
Zhang S; Jiang K; Zhang Q; Guo K; Liu Y
Glycoconj J; 2015 May; 32(3-4):119-25. PubMed ID: 25702281
[TBL] [Abstract][Full Text] [Related]
5. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.
Bai B; Lin Y; Hu J; Wang H; Li L; Zhao S; Zhang J; Meng W; Yue P; Bai Z; Li X
Oncol Rep; 2019 Mar; 41(3):1539-1548. PubMed ID: 30747220
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.
Dillon ST; Bhasin MK; Feng X; Koh DW; Daoud SS
J Transl Med; 2013 Oct; 11():239. PubMed ID: 24283668
[TBL] [Abstract][Full Text] [Related]
7. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
Zhang J; Hao N; Liu W; Lu M; Sun L; Chen N; Wu M; Zhao X; Xing B; Sun W; He F
Br J Cancer; 2017 Nov; 117(11):1676-1684. PubMed ID: 29024941
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Proteomics Analysis of Tissue Interstitial Fluid for Identification of Novel Serum Candidate Diagnostic Marker for Hepatocellular Carcinoma.
Sun W; Xing B; Guo L; Liu Z; Mu J; Sun L; Wei H; Zhao X; Qian X; Jiang Y; He F
Sci Rep; 2016 May; 6():26499. PubMed ID: 27216119
[TBL] [Abstract][Full Text] [Related]
9. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
11. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
[TBL] [Abstract][Full Text] [Related]
12. Proteome Differences between Hepatitis B Virus Genotype-B- and Genotype-C-Induced Hepatocellular Carcinoma Revealed by iTRAQ-Based Quantitative Proteomics.
Wei D; Zeng Y; Xing X; Liu H; Lin M; Han X; Liu X; Liu J
J Proteome Res; 2016 Feb; 15(2):487-98. PubMed ID: 26709725
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel diagnostic and prognostic biomarkers for hepatocellular carcinoma.
Wang F; Dong J; Zhang Y; Yue S; Guo H; Liang P; Zhou Y; Wei Y; Zhai W; Gao J
Oncol Rep; 2020 Jan; 43(1):87-98. PubMed ID: 31789422
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
15. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
[No Abstract] [Full Text] [Related]
16. Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma.
Zhang J; Ke M; Ren Y; Bi J; Du Z; Zhang M; Wang Y; Zhang L; Wu Z; Lv Y; Wu R
Dis Markers; 2019; 2019():9850191. PubMed ID: 31976024
[TBL] [Abstract][Full Text] [Related]
17. Identifying 13 Hub Genes Associated with Progression and Prognosis of Hepatocellular Carcinoma with Weighted Gene Co-Expression Network Analysis.
Liu Y; Cheng R; Chang Q; Wu Y; Liu C; Liu Y; Wu X; Cheng L; Hu L; Yin J
Crit Rev Eukaryot Gene Expr; 2021; 31(4):59-69. PubMed ID: 34587436
[TBL] [Abstract][Full Text] [Related]
18. Exosomal microRNAs as potential biomarkers for cancer cell migration and prognosis in hepatocellular carcinoma patient-derived cell models.
Yu LX; Zhang BL; Yang Y; Wang MC; Lei GL; Gao Y; Liu H; Xiao CH; Xu JJ; Qin H; Xu XY; Chen ZS; Zhang DD; Li FG; Zhang SG; Liu R
Oncol Rep; 2019 Jan; 41(1):257-269. PubMed ID: 30542726
[TBL] [Abstract][Full Text] [Related]
19. Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ-Based Quantitative Proteomic Analysis.
Zhang J; Liang R; Wei J; Ye J; He Q; ChunlingYuan ; Ye J; Li Y; Liu Z; Lin Y
Biomed Res Int; 2018; 2018():5484976. PubMed ID: 30345303
[TBL] [Abstract][Full Text] [Related]
20. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
Cao X; Cao Z; Ou C; Zhang L; Chen Y; Li Y; Zhu B; Shu H
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101583. PubMed ID: 33756265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
